Cyclerion Therapeutics Inc (NASDAQ:CYCN) — Market Cap & Net Worth
Market Cap & Net Worth: Cyclerion Therapeutics Inc (CYCN)
Cyclerion Therapeutics Inc (NASDAQ:CYCN) has a market capitalization of $2.25 Million ($2.25 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29976 globally and #6098 in its home market, demonstrating a 500.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyclerion Therapeutics Inc's stock price $23.94 by its total outstanding shares 668764 (668.76K). Also see how large is Cyclerion Therapeutics Inc's balance sheet for a full breakdown of the balance sheet.
Cyclerion Therapeutics Inc Market Cap History: 2019 to 2026
Cyclerion Therapeutics Inc's market capitalization history from 2019 to 2026. Data shows change from $36.38 Million to $16.01 Million (-26.91% CAGR). Also see Cyclerion Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Cyclerion Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #875 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2793 of 3165 |
Weight: Cyclerion Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cyclerion Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyclerion Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Cyclerion Therapeutics Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.41x
Cyclerion Therapeutics Inc's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $36.38 Million | $4.51 Million | -$123.01 Million | 8.07x | N/A |
| 2020 | $40.93 Million | $2.30 Million | -$77.80 Million | 17.83x | N/A |
| 2021 | $23.01 Million | $3.32 Million | -$51.65 Million | 6.93x | N/A |
| 2022 | $8.78 Million | $297.00K | -$44.08 Million | 29.55x | N/A |
| 2024 | $2.15 Million | $2.00 Million | -$3.06 Million | 1.08x | N/A |
| 2025 | $849.33K | $2.07 Million | -$3.53 Million | 0.41x | N/A |
Competitor Companies of CYCN by Market Capitalization
Companies near Cyclerion Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review Cyclerion Therapeutics Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cyclerion Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Cyclerion Therapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Cyclerion Therapeutics Inc's market cap moved from $36.38 Million to $ 16.01 Million, with a yearly change of -26.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.01 Million | +1785.04% |
| 2025 | $849.33K | -60.56% |
| 2024 | $2.15 Million | -3.88% |
| 2023 | $2.24 Million | -74.47% |
| 2022 | $8.78 Million | -61.85% |
| 2021 | $23.01 Million | -43.79% |
| 2020 | $40.93 Million | +12.50% |
| 2019 | $36.38 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Cyclerion Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.25 Million USD |
| MoneyControl | $2.25 Million USD |
| MarketWatch | $2.25 Million USD |
| marketcap.company | $2.25 Million USD |
| Reuters | $2.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cyclerion Therapeutics Inc
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an oral… Read more